Inogen, Inc. reported its financial results for the second quarter of 2026, revealing a total revenue of $95.1 million, a 3% increase from $92.3 million in the same period last year. The growth was primarily driven by a 5.5% rise in sales revenue, which reached $83.5 million, attributed to increased demand in international markets and favorable foreign exchange rates. However, rental revenue decreased by 11.8% to $11.6 million, reflecting a decline in the number of patients utilizing rental services. For the first half of 2026, total revenue was $180.2 million, up from $174.6 million in the prior year.

The company's gross profit for the second quarter was $43.3 million, representing a 4.7% increase compared to $41.3 million in Q2 2025. The gross margin improved to 45.5%, up from 44.8%, largely due to manufacturing cost efficiencies and reduced warranty-related costs. Despite these gains, Inogen reported a net loss of $3.9 million for the quarter, a slight improvement from a loss of $4.2 million in the previous year. For the first half of 2026, the net loss increased to $12.2 million from $10.3 million, primarily due to higher operating expenses.

Operationally, Inogen sold approximately 53,300 portable units in Q2 2026, a 12% increase from 47,600 units sold in Q2 2025. The company continues to focus on expanding its product offerings and geographic reach, particularly in Europe and other international markets. As of June 30, 2026, Inogen had cash and cash equivalents of $87.3 million, down from $103.7 million at the end of 2025, while total current assets decreased to $194.1 million from $198.3 million.

Inogen's strategic initiatives include investments in research and development to support new product launches and enhancements, as well as a share repurchase program authorized for up to $30 million, of which $7.5 million has been utilized to repurchase shares. The company is also working to optimize its rental revenue through targeted prescriber engagement and is leveraging partnerships to broaden its product portfolio. Looking ahead, Inogen anticipates continued growth in sales, particularly in international markets, while managing the challenges posed by market conditions and operational costs.

About Inogen Inc

Inogen, Inc. develops and markets portable oxygen concentrators and airway clearance devices for respiratory health. Its core products include the Inogen One and Rove systems for long-term oxygen therapy and the Simeox device for bronchiectasis treatment. Serving patients with COPD and other chronic respiratory conditions, the company emphasizes innovation, clinical evidence, and direct-to-consumer and provider sales channels to improve mobility and quality of life.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov